Moderna mRNA-based HIV vaccine, based in the United States, is preparing to begin phase-I clinical trials of the world’s first mRNA-based HIV vaccine.
It has been revealed that the HIV vaccine has been tested on 56 healthy persons who do not have HIV to determine its safety and basic immunological response.
“The success of our mRNA-based Coronavirus vaccine prompted us to pursue the development of an mRNA-based HIV vaccine,” Moderna CEO Stephane Bancel stated in remarks to the media.
Contemporary Pharmaceuticals has worked with the International AIDS Vaccine Initiative (IAVI) and the Bill & Melinda Gates Foundation to create the HIV vaccine (BMGF).
Contemporary Pharmaceuticals’ (Moderna) HIV vaccine, designated mRNA-1644, is built on the same mRNA technology as the company’s very effective COVID-19 immunotherapy. Moderna and Pfizer, both of which are situated in the United States, are the only two vaccine producers who have created COVID-19 vaccines based on mRNA strands of DNA.
Moderna will also begin clinical studies for mRNA-1644v2-Core, a variant of the HIV vaccine that is different from the original mRNA-1644.
Do you have something to say to the story? Please share it in the comments section below.